Bellerophon Therapeutics, Inc. Expected to Post Q2 2023 Earnings of ($0.39) Per Share (NASDAQ:BLPH)

Posted by Defense World Staff on May 20th, 2023

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) – Analysts at HC Wainwright lifted their Q2 2023 earnings per share (EPS) estimates for Bellerophon Therapeutics in a research report issued on Wednesday, May 17th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of ($0.39) per share for the quarter, up from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Bellerophon Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Bellerophon Therapeutics’ Q3 2023 earnings at ($0.41) EPS, Q4 2023 earnings at $0.13 EPS, FY2023 earnings at ($0.53) EPS, FY2024 earnings at ($0.37) EPS, FY2025 earnings at $0.07 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $2.01 EPS.

A number of other equities research analysts have also weighed in on BLPH. StockNews.com upgraded shares of Bellerophon Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Laidlaw initiated coverage on shares of Bellerophon Therapeutics in a research report on Tuesday, May 9th. They set a “buy” rating for the company.

Bellerophon Therapeutics Stock Down 16.3 %

Shares of NASDAQ BLPH opened at $7.92 on Friday. Bellerophon Therapeutics has a twelve month low of $0.67 and a twelve month high of $12.58. The firm has a market cap of $82.76 million, a P/E ratio of -6.49 and a beta of 0.89. The company has a 50 day moving average of $8.80 and a 200 day moving average of $4.13.

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last released its earnings results on Friday, March 31st. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLPH. HRT Financial LP acquired a new position in shares of Bellerophon Therapeutics in the fourth quarter worth about $25,000. Dimensional Fund Advisors LP purchased a new stake in Bellerophon Therapeutics during the 1st quarter valued at about $107,000. State Street Corp grew its stake in shares of Bellerophon Therapeutics by 41.3% in the 1st quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock valued at $238,000 after buying an additional 8,800 shares during the period. Renaissance Technologies LLC grew its stake in shares of Bellerophon Therapeutics by 13.0% in the 2nd quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 24,100 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Bellerophon Therapeutics by 49.0% in the 1st quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock valued at $755,000 after buying an additional 31,460 shares during the period. 11.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bellerophon Therapeutics news, major shareholder Life Science Opportu Puissance sold 560,000 shares of the company’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $9.46, for a total value of $5,297,600.00. Following the transaction, the insider now directly owns 1,211,262 shares in the company, valued at approximately $11,458,538.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 24.70% of the stock is currently owned by corporate insiders.

About Bellerophon Therapeutics

(Get Rating)

Bellerophon Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.